)
Marksans Pharma (MARKSANS) investor relations material
Marksans Pharma Q1 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q1 FY 2027 delivered record revenue of ₹841 crore (₹8,407.96 million), up 35.6% YoY, with highest ever quarterly EBITDA of ₹213 crore and PAT of ₹159 crore; cash balance crossed ₹1,000 crore for the first time.
Strategic investments in products, manufacturing, and international presence, especially in Europe, are translating into growth, profitability, and cash generation.
UK & Europe revenue surged 74.7% YoY to ₹356 crore, with QliniQ contributing ₹44 crore; Europe is now a key growth engine.
The quarter saw the acquisition of QliniQ B.V. in the Netherlands and a post-quarter agreement to acquire ABCnow GmbH in Germany, expanding European market presence.
Financial highlights
Operating revenue for Q1 FY 2027 was ₹840.8 crore, up 35.6% YoY; North America contributed ₹377 crore (+15.1% YoY), UK & Europe ₹356 crore (+74.7% YoY), Australia/NZ ₹88 crore (+33.7% YoY).
Gross profit rose to ₹497.3 crore (+38.9% YoY), with gross margin improving to 59.1% (+138 bps YoY).
EBITDA reached ₹213 crore (+112.8% YoY), with margin expanding to 25.3% (+919 bps YoY).
PAT was ₹159.4 crore (+173.9% YoY), PAT margin at 18.4% (+910 bps YoY).
Free cash flow for the quarter was ₹152 crore after net CapEx of ₹33 crore; working capital cycle improved to 132 days from 159 days YoY.
Outlook and guidance
FY 2027 guidance maintained at 15%-20% revenue growth and 20%-21% EBITDA margin, citing geopolitical volatility.
Management expects Q2 and Q3 revenues to be stronger than Q1, with Q3 likely the strongest.
Targeting ₹4,000 crore revenue within two years and doubling revenue within five years.
Recent acquisitions in the Netherlands and Germany are expected to strengthen the European footprint and distribution capabilities.
- FY26 saw record revenue, profit growth, margin gains, and continued global expansion.MARKSANS
Q4 25/26 - Q3 FY26 saw record revenue, margin gains, global expansion, and higher employee costs.MARKSANS
Q3 25/26 - Q2 FY26 saw 16% revenue and 70% net profit growth, with strong cash flow and expansion plans.MARKSANS
Q2 25/26 - Revenue up 5% YoY with margin gains, but profits fell on one-offs and forex losses.MARKSANS
Q1 25/26 - Q2 FY25 revenue grew 20.8% year-on-year, with record EBITDA and strong U.S. growth.MARKSANS
Q2 24/25 - Q1 FY25 saw strong revenue and profit growth, margin gains, and new facility ramp-up.MARKSANS
Q1 24/25 - Record Q3 PAT and robust U.S. growth drive strong results and positive outlook.MARKSANS
Q3 24/25 - FY25 saw record revenue and profit, led by 35% US growth, OTC strength, and margin expansion.MARKSANS
Q4 24/25
Next Marksans Pharma earnings date
Next Marksans Pharma earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage